Literature DB >> 12807272

Antibiotic prescribing for upper respiratory-tract infections in primary care.

Craig A Patterson1, Judith M Mackson, Lynn M Weekes.   

Abstract

The use and overuse of antibiotics in humans is a major contributor to the selection of antibiotic resistance organisms. Recent evidence has shown that primary care prescribing selects for resistances of clinical importance. The National Prescribing Service runs both educational and audit activities. The latter provide some insight into general practice attitudes toward antibiotic prescribing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12807272

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  4 in total

1.  Impact on antibiotic prescription of rapid antigen detection testing in acute pharyngitis in adults: a randomised clinical trial.

Authors:  Carl Llor; Jordi Madurell; Montse Balagué-Corbella; Mónica Gómez; Josep Maria Cots
Journal:  Br J Gen Pract       Date:  2011-05       Impact factor: 5.386

2.  Diagnosing streptococcal sore throat in adults: randomized controlled trial of in-office aids.

Authors:  Graham Worrall; James Hutchinson; Gregory Sherman; Joseph Griffiths
Journal:  Can Fam Physician       Date:  2007-04       Impact factor: 3.275

3.  Assessing the appropriateness of the management of upper respiratory tract infection in Australian children: a population-based sample survey.

Authors:  Janet C Long; Helena M Williams; Shefali Jani; Gaston Arnolda; Hsuen P Ting; Charlotte J Molloy; Peter D Hibbert; Kate Churruca; Louise A Ellis; Jeffrey Braithwaite
Journal:  BMJ Open       Date:  2019-05-14       Impact factor: 2.692

4.  Relationship between antimicrobial-resistance programs and antibiotic dispensing for upper respiratory tract infection: An analysis of Australian data between 2004 and 2015.

Authors:  Jianyun Wu; Daniel Taylor; Ludmila Ovchinikova; Aine Heaney; Tessa Morgan; Jonathan Dartnell; Rachel Holbrook; Lauren Humphreys; Lynn Weekes; Suzanne Blogg
Journal:  J Int Med Res       Date:  2018-01-14       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.